Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
Not Applicable
Withdrawn
- Conditions
- End Stage Renal Disease
- Registration Number
- NCT00167791
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
This is a study of patients who have a high risk of kidney rejection before kidney transplant. The hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from a donor who previously did not present a good match.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Active status on a kidney transplant waiting list with positive cross match against a living donor
Exclusion Criteria
- Receipt of a live vaccine within 4 weeks prior to randomization
- Previous Treatment with Rituximab
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Conversion of a positive donor specific cross-match to a living donor to a negative cross-match thereby allowing successful transplantation. assess 4 weeks after Rituximab treatment completed Transplant success or failure following the desensitization protocol. ongoing assessment for 2 years after transplant
- Secondary Outcome Measures
Name Time Method Decrease in incidence of humoral rejection to less than 50% at 1 year. assess 1 year after transplant
Trial Locations
- Locations (1)
University of Wisconsin
🇺🇸Madison, Wisconsin, United States